Status:
TERMINATED
Measurement of Smoking-Induced Neutrophil Activation
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
COPD
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
Neutrophil involvement in the development of COPD by smokers is well recognised. However not all smokers develop overt lung disease. We have previously shown that uptake of FDG is related to neutrophi...
Detailed Description
Asymptomatic smokers will be recruited by advertisement in newspapers and from posters displayed in the local community.Patients will be recruited from Hammersmith Hospital NHS Trust and local GP surg...
Eligibility Criteria
Inclusion
- Male smokers \>10 pack.year history,
- FEV1\>80% predicted,
- no relevant medical or mental disorder, able to give informed consent and
- Patients with COPD,
- \>20 pack.year history,
- no other active lung disease,
- FEV1\<70%
- FEV1/VC\<70%,
- no other relevant medical or mental disorder, able to give informed consent
Exclusion
- Female asymptomatic smokers
- ex-smokers
- other lung disorder
- relevant medical or mental illness
- recent (within 1 month) chest infection
- diabetes
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00159354
Start Date
June 1 2005
End Date
December 1 2006
Last Update
October 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hammersmith Campus
London, United Kingdom, W12 0NN